Revised rofecoxib labeling adds GI safety benefit, cardiovascular risk

News
Article

Merck has issued revised labeling for its COX-2 inhibitor rofecoxib (Vioxx) that incorporate findings from the 8,000-patient VIGOR (Vioxx Gastrointestinal Outcomes Research) study.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.